Chapter 15: Drug Product Formulation Development and Formulation Robustness Criteria for a mAb in a Pre-filled Syringe
- 14 March 2020
- book chapter
- Published by Springer Nature
- p. 373-389
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A Formulation Development Approach to Identify and Select Stable Ultra–High-Concentration Monoclonal Antibody Formulations With Reduced ViscositiesJournal of Pharmaceutical Sciences, 2017
- Application of QbD Principles to Late-Stage Formulation Development for Biological Liquid Products2015
- Specific Decrease in Solution Viscosity of Antibodies by Arginine for Therapeutic FormulationsMolecular Pharmaceutics, 2014
- The Role of Amino Acid Sequence in the Self-Association of Therapeutic Monoclonal Antibodies: Insights from Coarse-Grained ModelingThe Journal of Physical Chemistry B, 2013
- Coarse-Grained Modeling of the Self-Association of Therapeutic Monoclonal AntibodiesThe Journal of Physical Chemistry B, 2012
- Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction ParameterBiophysical Journal, 2012
- Syringe Siliconization Process Investigation and OptimizationPDA Journal of Pharmaceutical Science and Technology, 2012
- Tungsten-induced protein aggregation: Solution behaviorJournal of Pharmaceutical Sciences, 2009
- Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Antibody in Aqueous SolutionJournal of Pharmaceutical Sciences, 2005
- Challenges in the development of high protein concentration formulationsJournal of Pharmaceutical Sciences, 2004